IMMUNOHISTOCHEMICAL BIOMARKERS IN EC 115 5 Postoperative histology Tumor grade 1-2 607 (79.6) 3 156 (20.4) Histology Endometrioid 714 (93.6) Non-endometrioid 49 (6.4) FIGO stage I-II 675 (88.5) IA 428 (56.1) IB 196 (25.7) II 51 (6.7) III - IVB 88 (11.5) IIIA 20 (2.6) IIIB 4 (0.5) IIIC 43 (5.6) IVA 2 (0.3) IVB 19 (2.5) Lymph node status Positive (N1) 53 (6.9) Negative (N0) 440 (57.7) Unknown† (Nx) 270 (35.4) ESMO-ESGO-ESTRO risk classification Low 366 (48.0) Intermediate 140 (18.3) High-Intermediate 68 (8.9) High 169 (22.1) Advanced/Metastatic 20 (2.6) Adjuvant treatment None 415 (54.4) Radiotherapy 283 (37.1) VBT 112 (39.6) EBRT 104 (36.7) EBRT+VBT 93 (32.9) Chemotherapy 38 (5.0) Chemoradiation 26 (3.4) Not specified 1 (0.1) Outcome Recurrence 105 (13.8) Local 25 (23.8) Regional 9 (8.6) Distant 69 (65.7) Not classified 2 (1.9) Mortality Overall 102 (13.4) EC-related 61 (8.0) Data is presented in number (%), mean ± standard deviation (SD). EC, endometrial cancer; ER/PR, estrogen receptor/progesterone receptor; ESMO-ESGO-ESTRO, European Society for Medical Oncology - European Society of Gynaecological Oncology - European SocieTy for Radiotherapy & Oncology; EBRT, external beam radiotherapy; FIGO, Federation International Gynaecology Obstetric; L1CAM, L1 cell-adhesion molecule; N, number; VBT, vaginal beam therapy †no lymphadenectomy performed Table 1. Continued
RkJQdWJsaXNoZXIy MTk4NDMw